FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions

Key claim: The FDA has approved a once-daily extended-release formulation of ruxolitinib (Jakafi XR) for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.

Abstract

FDA approved Jakafi XR (ruxolitinib) extended-release tablets as a once-daily formulation for treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease, addressing the evolving needs of MPN patients.

Why this matters

Pending synthesis.

Source

Link